LHNVD 301
Alternative Names: LHNVD-301Latest Information Update: 02 May 2024
At a glance
- Originator Longhorn Vaccines and Diagnostics
- Class Bacterial vaccines; Peptide vaccines; Tuberculosis vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Gram-positive infections; Tuberculosis
Most Recent Events
- 27 Apr 2024 Pharmacodynamics data from preclinical trial in Tuberculosis and Gram-positive infections released by Longhorn Vaccines and Diagnostics
- 15 Nov 2023 Pharmacodynamics data from preclinical trial in Tuberculosis and Gram-positive infections released by Longhorn Vaccines and Diagnostics
- 02 Nov 2023 Preclinical trials in Gram-positive infections (Prevention) in USA (unspecified route) prior to November 2023